



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Fang, et al.

Appln. No.: 09/910,483

Filed: July 19, 2001

Title: HUMANIZED ANTIBODIES

Atty. Docket No.: 014357-0278772

11/13/2003 SSESKE1 00000049 502212 09910483  
03 FC:1806 180.00 DA

Examiner: Wortman, D.

Group Art Unit: 1648

Certificate of Mailing Under 37 C.F.R. §1.8

I hereby certify that this correspondence along with any paper referred to as being attached) is being mailed to Addressee by service of the United States Postal Service addressed to the Director of Patents, MS: Patent Application, P.O. Box 1450, Alexandria, VA 22313-1450

By: Karyn F. Massie  
Karyn F. Massie

Date: 11/5/03

**INFORMATION DISCLOSURE STATEMENT**

Director of Patents  
MS: Patent Application  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Attached is Form PTO-1449 listing the enclosed citations submitted in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56.

Request Under Rule 97(c): A first action on the merits has been issued in this matter, please accept this Information Disclosure Statement under Rule 97(c) and find an "Authorization to Pay and Petition for Acceptance of Any Necessary Fees" to satisfy Rule 17(p) requiring payment of \$180.00. If the amount authorized is incorrect or insufficient, the Commissioner is hereby authorized to charge any fee required to the deposit account or to credit any overpayment to our deposit account and proceed to consider this Information Disclosure Statement.


This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

This Information Disclosure Statement is not to be constructed as a representation that any of the listed citations establishes, by itself or in combination with other information, a prima facie case of unpatentability of any claim in the above-identified patent application. Additionally, this Information Disclosure Statement is not to be constructed as a representation that a further search of the art has been made by the Applicant, or that additional information unknown to the Applicant and relevant to the examination of this patent application does not exist.

Consideration of the foregoing and enclosures plus the return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 are earnestly solicited along with an early action on the merits.

Respectfully submitted,

PILLSBURY WINTHROP LLP

A handwritten signature in black ink, appearing to read 'Robert M. Bedgood', is written over the printed name and contact information.

Robert M. Bedgood, Ph.D.

Reg. No 43,488

Tel. No. (858) 509-4065

Fax No. (858) 509-4010

11682 El Camino Real

Suite 200

San Diego, CA 92130-2593



FORM PTO-1449 (modified)  
U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office

To:

Atty.  
Dkt. No.

M#

Client Ref.

0278772

014357

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: FANG, Fang

Appln. No.: 09/910,483

Filing Date: July 19, 2001

Date: November 5, 2003

Page

1

of 1

Examiner: Wortman, D.

Group Art Unit: 1648

## U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						
CR						
DR						
ER						

## FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
FR	JP10-101699	10/1998	Japan			X		
GR								
HR								

## OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

IR	Ohtomo, et al., "Humanization of Mouse ONS-M21 Antibody With The Aid of Hybrid Variable Regions," (1995) <i>Molecular Immunology</i> , Vol. 1, No. 6, pp. 407-416.			
JR	Mateo, et al., "Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity," (1997), <i>Immunotechnology</i> , Vol. 3, pp. 71-81.	Yes		
KR	Nagahira, et al., "Humanization of a mouse neutralizing monoclonal antibody against tumor necrosis factor- $\alpha$ (TNF- $\alpha$ )," (1999), <i>Journal of Immunological Methods</i> , Vol. 222, pp. 83-92.	Yes		
LR	Saldanha, et al., "A single blackmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," (1999). <i>Molecular Immunology</i> , Vol. 36, pp. 709-719.	Yes		
MR	Tempest, et al., "Identification of framework residues required to restore antigen binding during reshaping of a monoclonal antibody against the glycoprotein gB of human cytomegalovirus," (1995), <i>Int. J. Biol. Macromol.</i> , Vol. 17, No. 1, pp. 37-42.	Yes		
NR	Carter, et al., "Humanization of an anti-p185(HER2) antibody for human cancer therapy," (1992), <i>Proc. Natl. Acad. Sci.</i> , Vol. 89, pp. 4285-4289.	Yes		
OR	Presta, et al., "Humanization of an Antibody Directed Against IgE," (1993), <i>Journal of Immunology</i> , Vol. 151, No. 5, pp. 2623-2632.	Yes		

Examiner

Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.